Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic diseases is undergoing a profound transformation, heralded by the recent approval of orforglipron, the first…
Read More
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
More than a decade ago, the American Society of Clinical Oncology (ASCO) initiated CancerLinQ, a pioneering platform designed with the…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The landscape of generic drug economics in the United States is undergoing a significant transformation, largely driven by the advent…
Read More
Insuring the Trip: An Underwriter on What It Will Take for Approved Psilocybin to Become a Real Business
More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, classified psilocybin as a…
Read More
PharmSci 360 2026 heads to New Orleans this October
The American Association of Pharmaceutical Scientists (AAPS) has announced that its premier annual gathering, PharmSci 360, will convene from October…
Read More
Moderna Bets on mRNA’s Second Act with Cancer, Autoimmune Programs, and AI Research Platform
At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…
Read More
Verseon bets physics can take drug design beyond AI’s training data
Bay Area-based pharmaceutical company Verseon has been a quiet pioneer in computational drug design since 2002, predating the widespread emergence…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A significant paradigm shift is underway in small-molecule drug discovery, as a pioneering collaboration between Ginkgo Datapoints, Tangible Scientific, and…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
